Although Gaucher disease is rare, there are numerous resources available to practitioners, patients and caregivers.

Gaucher Registry

The Gaucher Registry is the world’s largest cooperative observational study on Gaucher Disease. The Gaucher Registry is sponsored by Sanofi Genzyme and directed by the International Collaborative Gaucher Group(ICGG), a group of physicians who are experts in the management of Gaucher disease.

Sanofi Genzyme Support Services

Managing a genetic disease is a lifetime commitment. From diagnosis to treatment, our dedicated team of professionals is available to provide disease education and help address you patients' needs, including assistance with health insurance issues, all free of charge. 

Access to these and other services is voluntary, and you and your patients are not obligated to begin treatment if you contact us. You and your patients make all treatment-related decisions, and most importantly the privacy and security of their personal situation is always protected.

For more information, contact Sanofi Genzyme Support Services at 800-745-4447 (option 3), Monday-Friday 8:00 AM to 6:00 PM EST.

Additional Information

Additional information and support is available through professional medical organizations, hospitals, national and international Gaucher disease groups, patient support organizations, and medical centers specializing in Gaucher disease care and research. Click here for more information.

Indication & Usage

Cerezyme® (imiglucerase for injection) is indicated for long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions:

  1. anemia
  2. thrombocytopenia
  3. bone disease
  4. hepatomegaly or splenomegaly

Important Safety Information

Approximately 15% of patients have developed IgG antibodies to Cerezyme during the first year of therapy. Approximately 46% of patients with detectable IgG antibodies experienced symptoms of hypersensitivity, and these patients have a higher risk of hypersensitivity. It is suggested that patients be monitored periodically for IgG antibody formation during the first year of treatment.

Hypersensitivity has also been observed in patients without detectable IgG antibodies. Symptoms suggestive of hypersensitivity have been noted in approximately 6.6% of all patients, and anaphylactoid reactions in less than 1%. Treatment with Cerezyme should be approached with caution in patients who have exhibited hypersensitivity symptoms such as pruritus, flushing, urticarial, angioedema, chest discomfort, dyspnea, coughing, cyanosis, and hypotension. Pre-treatment with antihistamines and/or corticosteroids and a reduced rate of infusion may allow continued treatment in most patients.

In less than 1% of patients, pulmonary hypertension and pneumonia have been observed during treatment with Cerezyme. These are known complications of Gaucher disease regardless of treatment. Patients with respiratory symptoms in the absence of fever should be evaluated for the presence of pulmonary hypertension.

Approximately 13.8% of patients have experienced adverse events related to treatment with Cerezyme. Some of these are injection site reactions such as discomfort, pruritus, burning, swelling or sterile abscess at the site at the site of venipuncture. Additional adverse reactions that have been reported include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Transient peripheral edema has also been reported for this therapeutic class of drug.

To report suspected adverse reactions, contact Sanofi Genzyme at 800-745-4447, option 2

Please see Full Prescribing Information (PDF).